Antibody ID	ANI0RMKEH
Antibody Name	Anti-CD70 mAb IF6
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Humanized IgG
Antigen Name	CD70 antigen (CD70)					Antigen Info
Click to Show/Hide the Sequence Information of This Antibody

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	19.75%	Positive TNF expression (TNF+++/++)
Method Description	3 mg mAb component/kg in vivo therapeutic efficacy of the conjugates in nude mice(5 animals/group).
In Vivo Model	786-O human RCC cell line xenograft model
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	525 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1096 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1585 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	66.35%	Positive TNF expression (TNF+++/++)
Method Description	3 mg mAb component/kg in vivo therapeutic efficacy of the conjugates in nude mice(5 animals/group).
In Vivo Model	DBTRG-05MG glioblastoma cell line xenograft model
In Vitro Model	Anaplastic astrocytoma	DBTRG-05MG cells		CVCL_1169
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	93.15%	Positive TNF expression (TNF+++/++)
Method Description	3 mg mAb component/kg in vivo therapeutic efficacy of the conjugates in nude mice(5 animals/group).
In Vivo Model	786-O human RCC cell line xenograft model
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	11 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	20 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	24 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	84.59%	Positive TNF expression (TNF+++/++)
Method Description	3 mg mAb component/kg in vivo therapeutic efficacy of the conjugates in nude mice(5 animals/group).
In Vivo Model	DBTRG-05MG glioblastoma cell line xenograft model
In Vitro Model	Anaplastic astrocytoma	DBTRG-05MG cells		CVCL_1169
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	85.01%	Positive TNF expression (TNF+++/++)
Method Description	1 mg mAb component/kg in vivo therapeutic efficacy of the conjugates in nude mice(5 animals/group).
In Vivo Model	786-O human RCC cell line xenograft model
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	93.25%	Positive TNF expression (TNF+++/++)
Method Description	3 mg mAb component/kg in vivo therapeutic efficacy of the conjugates in nude mice(5 animals/group).
In Vivo Model	786-O human RCC cell line xenograft model
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5.90±2.00 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	6.10±2.70 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	9.10±3.60 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	86.68%	Positive TNF expression (TNF+++/++)
Method Description	3 mg mAb component/kg in vivo therapeutic efficacy of the conjugates in nude mice(5 animals/group).
In Vivo Model	DBTRG-05MG glioblastoma cell line xenograft model
In Vitro Model	Anaplastic astrocytoma	DBTRG-05MG cells		CVCL_1169
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	92.40%	Positive TNF expression (TNF+++/++)
Method Description	3 mg mAb component/kg in vivo therapeutic efficacy of the conjugates in nude mice(5 animals/group).
In Vivo Model	786-O human RCC cell line xenograft model
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	9 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	12 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	168 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	92.33%	Positive TNF expression (TNF+++/++)
Method Description	3 mg mAb component/kg in vivo therapeutic efficacy of the conjugates in nude mice(5 animals/group).
In Vivo Model	DBTRG-05MG glioblastoma cell line xenograft model
In Vitro Model	Anaplastic astrocytoma	DBTRG-05MG cells		CVCL_1169
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	95.90%	Positive TNF expression (TNF+++/++)
Method Description	3 mg mAb component/kg in vivo therapeutic efficacy of the conjugates in nude mice(5 animals/group).
In Vivo Model	786-O human RCC cell line xenograft model
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	12 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	24 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	28 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	93.39%	Positive TNF expression (TNF+++/++)
Method Description	3 mg mAb component/kg in vivo therapeutic efficacy of the conjugates in nude mice(5 animals/group).
In Vivo Model	786-O human RCC cell line xenograft model
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	44 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	275 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	339 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	93.88%	Positive TNF expression (TNF+++/++)
Method Description	1 mg mAb component/kg in vivo therapeutic efficacy of the conjugates in nude mice(5 animals/group).
In Vivo Model	786-O human RCC cell line xenograft model
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	15 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	16 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	19 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	93.91%	Positive TNF expression (TNF+++/++)
Method Description	1 mg mAb component/kg in vivo therapeutic efficacy of the conjugates in nude mice(5 animals/group).
In Vivo Model	786-O human RCC cell line xenograft model
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	20 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	20 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	28 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	95%	Positive TNF expression (TNF+++/++)
Method Description	3 mg mAb component/kg in vivo therapeutic efficacy of the conjugates in nude mice(5 animals/group).
In Vivo Model	DBTRG-05MG glioblastoma cell line xenograft model
In Vitro Model	Anaplastic astrocytoma	DBTRG-05MG cells		CVCL_1169
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	98.65%	Positive TNF expression (TNF+++/++)
Method Description	3 mg mAb component/kg in vivo therapeutic efficacy of the conjugates in nude mice(5 animals/group).
In Vivo Model	786-O human RCC cell line xenograft model
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	9 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	10 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	7 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	6 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	6 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	11 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	7 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	7 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	9 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	8 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	10 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	123 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	8 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	8 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	9 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	18 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	18 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	25 ng/mL	Positive CD70 expression (CD70+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	20 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	22 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	39 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	56 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1000 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 10 uM	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 10 uM	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 10 uM	Positive TNF expression (TNF+++/++)
Method Description	IC50 values are the mean and SD of 21 independent experimental titrations, each performed at least in duplicate.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Ref 1	Novel Peptide Linkers for Highly Potent Antibody-Auristatin Conjugate.